4Wisplinghoff H,Bischoff T,Taltent SM,et al. Nosocomial bloodstream infections in US hospitals:Analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis,2004,39(3) :309 -317.
6Feja KN, Wu F, Roberts K, et al. Risk factors for candidemia in critically ill infants: A matched case - control study [ J ]. J Pediatr, 2005,147 (2) :156 -161.
4Walsh TJ,Anaissie EJ,Denning DW, et al.Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America [J].Clin Infect Dis,2008,46(3):327-360.
5Pappas PG,Kauffman CA,Andes D,et al.Clinical practice guidelines for the management of candidiasis[J].Clin Infect Dis,2009,48(8): 1042-1051.
6Conde - Rosa A, Amador R, P6rez - Torres D, et al. Candidemia distri- bution, associated risk factors, and attributed mortality at a university - based medical center[ J ]. P R Health Sei J,2010,29 (1) :26 -29.
7Singh - Naz N,Sprague BM, Patel KM,et al. Risk assessment and stan- dardized nosocorrial infection rate in criticaly ill children [ J ]. Crit Care Med,2000,28 ( 6 ) :2069 - 2075.
8Grover ND. Echinocandins : A ray of hope in antifungal drug therapy[ J].Indian J Pharmacol ,2010,42 (1):9-11.
10Yoshizawa S, Gotoh M, Kitahara T,e. al. Micafungin - induced hemoly-sis attack due to drug - dependent antibody persisting for more than 6weeks[ J]. Leuk Res,2010,34(2) ;e60 - e61.
